Silver Book Fact

Nerve growth factor (NGF) has been found to be a major mediator of inflammatory and neuropathic pain and provides a new therapeutic target.

Watson J, Allen S, Dawbarn D. Targeting New Growth Factor in Pain: What is the therapeutic potential?. BioDrugs. 2008; 22(6): 349-59. http://www.mendeley.com/catalog/targeting-nerve-growth-factor-pain-therapeutic-potential/

Reference

Title
Targeting New Growth Factor in Pain: What is the therapeutic potential?
Publication
BioDrugs
Publication Date
2008
Authors
Watson J, Allen S, Dawbarn D
Volume & Issue
Volume 22, Issue 6
Pages
349-59
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • Opioids have been found to reduce pain intensity and improve physical functioning for patients with persistent noncancer pain. It’s important to note that a decrease in mental health functioning…  
  • Antiepileptic drugs relieve persistent neuropathic pain. One meta-analysis found gabapentin to be associated with moderate benefit (equivalent to 30% pain relief) in close to 1 in 2 patients, and…  
  • Advances in neuroimaging will continue to offer information on the brain’s functioning and how it correlates to the pain experience.  
  • In individuals with persistent low back pain, tanezumab, a humanized anti-nerve growth factor antibody, showed clinical and statistical analgesic efficacy that was superior to placebo and naproxen.  
  • People with persistent pain who used complementary and alternative medicine (CAM) had lower average health care expenditures than nonusers ($3,797 versus $4,153).